BCL2 and B-cell chronic lymphocytic leukemia: Since its FDA approval in 2016, Venetoclax, which targets the anti-apoptotic protein BCL2, has been administered to patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML)39.